Related Experiment Video

Updated: Feb 2, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.6K

Targeting tyrosine kinases for treatment of ocular tumors

Dong Hyun Jo1,2, Jin Hyoung Kim1,2, Jeong Hun Kim3,4,5,6

  • 1Fight Against Angiogenesis-Related Blindness (FARB) Laboratory, Clinical Research Institute, Seoul National University Hospital, Seoul, 03080, Republic of Korea.

Archives of Pharmacal Research
|November 25, 2018
PubMed

Insights

Targeted therapies show promise for treating ocular tumors like uveal melanoma and retinoblastoma. By inhibiting tyrosine kinases, these treatments may improve outcomes and preserve vision, offering new hope beyond conventional methods.

Area of Science:

  • Ophthalmology
  • Oncology
  • Molecular Biology

Background:

  • Uveal melanoma and retinoblastoma are primary ocular malignancies in adults and children, respectively.
  • Current treatments like chemotherapy and enucleation have limitations.
  • Targeted therapies offer potential for improved outcomes and eyeball preservation.

Purpose of the Study:

  • To review the role of tyrosine kinases in ocular tumors.
  • To explore targeted therapy strategies for uveal melanoma and retinoblastoma.
  • To highlight tyrosine kinase inhibitors as potential novel treatments.

Main Methods:

  • Literature review focusing on tyrosine kinases in ocular oncology.
  • Analysis of molecular mechanisms in uveal melanoma and retinoblastoma.
  • Synthesis of current and emerging therapeutic approaches.

Main Results:

  • Tyrosine kinases (receptor and non-receptor) are crucial in ocular tumor cell signaling.
  • Targeting these kinases can modulate proliferation, differentiation, and attachment.
  • Tyrosine kinase inhibitors represent a promising therapeutic avenue.

Conclusions:

  • Targeted inhibition of tyrosine kinases offers a new strategy for ocular tumor treatment.
  • This approach may enhance conventional therapies for uveal melanoma and retinoblastoma.
  • Further research into tyrosine kinase inhibitors could expand treatment options and improve vision preservation.
Keywords:
RetinoblastomaTyrosine kinaseTyrosine kinase inhibitorUveal melanoma

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.3K
Nasolacrimal Lavage as a Treatment for Ocular Surface Toxic Soup Syndrome03:40

Nasolacrimal Lavage as a Treatment for Ocular Surface Toxic Soup Syndrome

Published on: April 25, 2025

1.1K

Related Concept Videos

Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
18.6K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
535
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.1K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

4.5K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.5K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
996